Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
| ▸ | C1R | P00736 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26894571 | 0.85 | L3MBTL1 (0.59) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL9631014 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL14315671 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL11791959 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HTTGAATDP1L3MBTL1 | |
| SCHEMBL25129316 | 0.80 | ALDH1A1 (0.64) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL12497077 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL29706057 | 0.80 | L3MBTL1 (0.50) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL24359580 | 0.80 | GAA (0.50) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL22204652 | 0.80 | L3MBTL1 (0.50) | ALDH1A1HTTGAATDP1ALOX15 | |
| SCHEMBL29010803 | 0.80 | ALOX15 (0.50) | ALDH1A1HTTGAATDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116019794-A | Application of amino fullerene material in preparation of exosome PD-L1 inhibition drugs | 中国科学院化学研究所 | 2023-04-28 | — | — | CN | disclosed |
| EP-1456181-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | Pfizer Products Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6753334-B2 | PREPARING A PHENYL OR QUINOLINYL HYDRAZINE BY REDUCING THE CORRESPONDING DIAZONIUM SALT WITH ASCORBIC ACID AND HEATING; COLORLESS PRODUCT; INTERMEDIATES TO DRUGS FOR REDUCING TISSUE DAMAGE FROM ISCHEMIA OR HYPOXIA | PFIZER, INC. | 2004-06-22 | — | — | US | disclosed |
| US-6627643-B2 | Sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I' are useful for the prevention and treatment of myocardial ischemic injury. Myocardial ischemic injury can occur in out-patient in perioperative settings and can lead to sudden | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1337508-A1 | PREPARATION OF SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2003051845-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030119873-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | LAMBERT JOHN F (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002044133-A1 | PREPARATION OF SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0215312-B1 | METHOD FOR PRODUCING OF POLYARYLENE SULFIDES | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1992-03-25 | — | — | EP | disclosed |
| US-4810773-A | HIGH MOLECULAR WEIGHT ENGINEERING THERMOPLASTICS | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 1989-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119873-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | NHERF1, SLC9A1, SLC9A2 | ALDH1A1 637/4885HTT 1041/4885GAA 671/4885 |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | SLC9A1, NHERF1, SLC9A5 | ALDH1A1 531/4885HTT 656/4885GAA 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.